Posted by Michael Wonder on 08 Jan 2025
Rezolute receives breakthrough therapy designation from FDA for ersodetug in the treatment of hypoglycaemia due to congenital hyperinsulinism
7 January 2025 - Breakthrough therapy designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism.
Rezolute today announced that the US FDA has granted breakthrough therapy designation to ersodetug (RZ358) for the treatment of hypoglycaemia due to congenital hyperinsulinism.
